Abstract Aims: To compare the efficacy and tolerability of Oxymetazoline 0.05 % plus Dexpanthanol 5% versus Xylometazoline 0.1 % nasal drops in patients with nasal congestion due to allergic rhinitis and following nasal surgery.
Introduction
Among the leading causes of nasal congestion, allergic rhinitis, infective rhinitis and post-operative nasal congestion head the list. If untreated, it leads to deterioration of quality of life and can interfere with hearing and speech development. It causes loss of work days and productivity. Chronic nasal congestion can lead to sinusitis with its accompanying morbidity and complications. Nasal congestion is also a common problem in the post -operative period after nasal surgery.
Nasal decongestants induce vasoconstriction via alpha receptor activation and reduce swelling of the mucosa, thus assisting in nasal as well as sinus drainage. Oxymetazoline and xylometazoline are commonly used long acting nasal decongestants. Rebound congestion and local irritation on instillation are the two factors that can limit their use. Dexpanthenol, a precursor to pantothenic acid, has lately been tried in combination with nasal decongestants in order to overcome some of the shortcomings of the latter. The combination of nasal decongestants with dexpanthenol has been proven to have a synergistic effect, which is clinically superior to that of the decongestant alone and also shortens the treatment time in allergic rhinitis.
1 It is also an epithelial protective agent and is also known to accelerate wound healing [1] [2] [3] , an effect which could be useful in the postoperative period. The present study was undertaken to verify the validity of the above claims.
Objective
To compare the efficacy and tolerability of Oxymetazoline 0.05 % plus Dexpanthanol 5% versus Xylometazoline 0.1 % nasal drops in patients with nasal congestion due to allergic rhinitis and following nasal surgery.
Patients And Methods
The study was an investigator-blind, randomized, controlled, phase IV clinical trial conducted in 100 patients attending the OPD at the ENT department at JJ Hospital, Mumbai. The study was initiated after an approval from the IRB of SNC and Sir JJ Group of Hospitals. Patients of either sex between 18 to 60 years of age with acute allergic rhinitis presenting with signs & symptoms of nasal congestion or patients postnasal surgery like septoplasty or polypectomy, who gave their informed consent and can could come for follow-up as per the study schedule.
Exclusion Criteria Patients on screening were assigned a serial number as per the chronological order. After the patient was found to be eligible and satisfying the inclusion criteria, the sealed study medication pack was opened to reveal the study medication. Randomization was done on the basis of a PC based software (Rando version 1.2, © R. Raveendran 2004) and the patients were randomized into two groups. The study was conducted for a period of 6 days. Patients could withdraw from the study at their own request or at the discretion of the investigator anytime during the study. In all cases, the reasons for the patient's withdrawal were entered in the CRF. One group received Oxymetazoline HCl 0.05 % with Dexpanthanol 5% (OD) and the second group received Xylometazoline HCl 0.1 % (XO) in the form of nasal drops which were administered four times a day.
Patients were not allowed to take the following medications: -Any other systemic or nasal decongestants, -Glucocorticosteroids in any form. Patients were allowed to take the following preparations, provided they were prescribed by the investigator: -Antimicrobial agents for post nasal surgery patients, -Antihistaminic agents.
Any concomitant treatment given to or taken by the patient was recorded in the case record form. Patients were assessed clinically during screening and then on days 2, 4 & 6 of study therapy. On the first day, the patients were provided a diary and they were required to fill the symptom severity in the diary to assess the symptom relief after first dose & rebound congestion.
Statistical methods
The two treatments groups were analyzed for baseline comparability using unpaired 't' test. After they were found comparable, the change in clinical parameters between groups was analyzed by Mann-Whitney 'U' test (non-parametric). Change in clinical parameters from baseline values at followup visits in the treatment groups was analyzed by Friedman test (non-parametric). Adverse events will be compared using Chi-Square test.
Results
Out of a total of 100 patients enrolled in the study, five were lost to follow up (two in OD group and 3 in XO group). A total of 95 patients were evaluated for the study (48 OD and 47 XO group). Both the treatment groups were comparable as far as age, weight and height were concerned. There was no significant difference between the two groups with respect to sex of the patients or to the indication for therapy. [ Table  - 1]
Nasal congestion
Nasal congestion was relieved as early as the first hour by both the medications. It was observed that as early as the second hour, relief from nasal congestion was significantly more (p< 0.05) in the OD group then the XO group. This difference was maintained till the end of the observation period of six hours. When nasal congestion was assessed over six days, the improvement seen in the OD group (mean score of 1.24) was significantly more than that in the XO group (mean score of 1.86) on the second day (p<0.05) as well as on the fourth day (0.25 in OD group Vs 0.64 in the XO group, p<0.05). The relief in nasal congestion is significantly better in the OD group then in the XO group.
Sneezing: There was a considerable improvement in sneezing in both the treatment groups within the first hour. The mean sneezing scores were 0.40, 0.30 and 0.20 for the OD group at the end of one, two and three hours respectively whereas mean sneezing scores for the XO group were 0.70, 0.43 and 0.45 at the end of one, two and three hours respectively. The difference between the two groups was statistically significant 
